Dr. Gilbert Describes Ongoing RTOG 0825 Trial Analyses

Name: Dr. Gilbert Describes Ongoing RTOG 0825 Trial Analyses
Uploaded: 2013-06-03T10:03:55.000Z
Description: Mark R. Gilbert, MD, from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.

June 3, 2013

Mark R. Gilbert, MD

Video

Conference|ASCO Annual Meeting

Mark R. Gilbert, MD, from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.

Mark R. Gilbert, MD, a professor of neuro-oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.

Several components of the 0825 trial are still under evaluation, including a composite interpretation of progression-free survival that includes data on quality of life and neurocognitive function. Gilbert believes these endpoints are a pivotal component that should be included as part of the composite analysis for all clinical trials.

Additionally, a secondary analysis of MGMT and a 9 gene molecular profile is still under way to determine if patients can be identified who benefited the most from treatment with bevacizumab in the first-line setting.